Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
55.7M
-
Number of holders
-
44
-
Total 13F shares, excl. options
-
11.1M
-
Shares change
-
-4.03M
-
Total reported value, excl. options
-
$32.1M
-
Value change
-
-$7.95M
-
Number of buys
-
24
-
Number of sells
-
-19
-
Price
-
$2.90
Significant Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) as of Q2 2025
57 filings reported holding SPRO - Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2025.
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) has 44 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11.1M shares
of 55.7M outstanding shares and own 19.89% of the company stock.
Largest 10 shareholders include Pfizer Inc (2.36M shares), VANGUARD GROUP INC (1.95M shares), Anson Funds Management LP (1.62M shares), Alphabet Inc. (890K shares), RENAISSANCE TECHNOLOGIES LLC (832K shares), Schonfeld Strategic Advisors LLC (511K shares), GEODE CAPITAL MANAGEMENT, LLC (511K shares), BlackRock, Inc. (435K shares), MONIMUS CAPITAL MANAGEMENT, LP (311K shares), and Informed Momentum Co LLC (239K shares).
This table shows the top 44 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.